WisdomTree U.S. ESG Fund

Revenue was $311.6 million versus $266.6 million a year ago, up 17% overall. Gross margin was $167 million, or about 54%, versus roughly 53% in the prior-year quarter, with management citing M Series/manufacturing efficiencies but also lower-margin oxygen and home respiratory mix. Operating income was $32.8 million, pre-tax income was $37.5 million, net income was $27.5 million, and diluted EPS was $0.37; management said there were roughly $6.3 million of favorable one-time items offset by $5.4 million of in-process R&D and about $1 million of accelerated R&D. For the full year, revenue guidance was raised from $1.36 billion to $1.38 billion, EPS guidance was raised to $1.93-$1.98, and cash flow guidance was raised from $120 million to $125 million.

John Miclot framed the quarter as evidence that the company’s strategy is working, pointing to broad-based growth across products and geographies and saying the refreshed product line and international expansion are driving share gains. He highlighted strong acceptance of Auto A-Flex, continued adoption of OptiLife, and upcoming launches in patient interfaces and ventilators. His tone was confident and upbeat, but still focused on long-term execution in sleep, ventilation, and broader respiratory markets.

Dan Bevevino walked through the quarter in detail, noting domestic sleep revenue of $134.9 million, international sleep of $49.4 million, total revenue of $311.6 million, and gross margin of about 54%. He said SG&A, R&D, and the $5.4 million in-process R&D charge pressured operating income, but that the quarter still would have met guidance absent one-time items. He also said cash and short-term investments increased $15 million to $322 million after $14 million of acquisitions, operating cash flow was $38.5 million, DSO was 62 days, total debt was just under $50 million, and net cash flow guidance for the year was increased to $125 million.

Analysts pressed on new patient interfaces, EverFlo/EverGo margin impact, the sleep market and pricing, the Apollo Light acquisition, the oximetry exit, international share gains, tax rate, and the ventilator roadmap. Management said a full-face mask is the best enhancement opportunity, that EverFlo/EverGo are being well received and were already built into gross margin guidance, and that the sleep market remains healthy rather than price-pressured. On acquisitions and strategy, they emphasized a disciplined mix of technology, licensing, equity investments, and international distribution deals, and said non-invasive ventilation remains the primary ventilator focus, while home invasive remains a smaller area of interest.